Experimental Characterization of the Binding Affinities between Proapoptotic BH3 Peptides and Antiapoptotic Bcl‐2 Proteins
- 7 August 2018
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 13 (17) , 1763-1770
Abstract
The Bcl‐2 family proteins are key regulators of the intrinsic apoptotic pathway and are among the validated targets for developing anticancer drugs. Protein–protein interactions between the pro‐ and antiapoptotic members of this family determine mitochondrial outer‐membrane permeabilization. Elucidating such protein–protein interactions in a quantitative way is helpful for network pharmacology studies on the Bcl‐2 family, which, in turn, will provide valuable guidance for developing new anticancer therapies. In this study, the binding affinities of the BH3 peptides derived from eight proapoptotic BH3‐only proteins (i.e., Bid, Bim, Puma, Noxa, Bad, Bmf, Bik, Hrk) against five well‐studied antiapoptotic proteins (i.e., Bcl‐xL, Bcl‐2, Mcl‐1, Bcl‐w, Bfl‐1) in the Bcl‐2 family have been measured. Three different types of binding assay (i.e., surface plasmon resonance, fluorescence polarization, and homogeneous time‐resolved fluorescence) were employed for cross‐validation. The results confirmed that each proapoptotic BH3 peptide exhibited a distinct binding profile against the five antiapoptotic proteins. The binding data obtained herein serve as a fresh update or correction to existing knowledge. It is expected that such binding data will be helpful for building more accurate mathematical network models for depicting the complex protein–protein interactions within the Bcl‐2 family.Keywords
Funding Information
- National Natural Science Foundation of China (81725022, 81430083, 21472227, 21673276, 21402230)
- Ministry of Science and Technology of the People's Republic of China (2016YFA0502302)
- Chinese Academy of Sciences (XDB20000000, XDB20020200)
This publication has 44 references indexed in Scilit:
- BH3 Mimetics: Status of the Field and New DevelopmentsMolecular Cancer Therapeutics, 2013
- Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteinsBMC Biotechnology, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 ProteinsJournal of Biological Chemistry, 2009
- Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial ApoptosisMolecular Cell, 2009
- A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradationJournal of Cell Biology, 2008
- BH3 mimetics to improve cancer therapy; mechanisms and examplesDrug Resistance Updates, 2007
- Structural insights into the degradation of Mcl-1 induced by BH3 domainsProceedings of the National Academy of Sciences, 2007
- NMR determination that an extended BH3 motif of pro-apoptotic BID is specifically bound to BCL-XLMagnetic Resonance in Chemistry, 2006